MDxHealth SA reports developments in urology-focused precision diagnostics, including molecular tests used in the diagnosis and prognosis of prostate cancer and other urologic diseases. The company’s test menu is based on genomic, epigenomic, exosomal and other molecular technologies and includes products such as Confirm mdx, GPS mdx, ExoDx, Select mdx and Resolve mdx.
Recurring news for MDXH includes financial results, revenue guidance, tissue-based and liquid-based test volumes, clinical data for the Genomic Prostate Score test, and collaborations with academic prostate cancer researchers. Company updates also cover the integration of Exosome Diagnostics, earnout and warrant arrangements tied to diagnostic-test acquisitions, and corporate governance or management changes.
mdxhealth (NASDAQ: MDXH) reported fourth-quarter 2025 revenue of $29.5M (+19%) and full-year 2025 revenue of $107.9M (+20%). Gross profit rose to $69.6M for 2025 with gross margin at 64.5%. Adjusted EBITDA improved to ($1.1M) for 2025. Cash was $29.0M at year-end. The company reaffirmed 2026 revenue guidance of $137–140M and targets a 10% adjusted EBITDA margin exiting 2026.
MDxHealth (NASDAQ: MDXH) will release fourth quarter and full year 2025 financial results after market close on February 26, 2026. A conference call and live webcast with Q&A is scheduled for February 26, 2026 at 4:30pm ET / 22:30 CET.
Investors can join via listed dial‑in numbers or the provided webcast link and should connect 15 minutes early; a replay will be available on the company website.
MDxHealth (NASDAQ: MDXH) reported preliminary Q4 and full-year 2025 results and issued 2026 revenue guidance. The company expects Q4 2025 revenue of approximately $30.5M and full-year 2025 revenue of $109M, representing year-over-year growth of 23% and 21%, respectively. Volume highlights include 11,201 tissue-based and 27,486 liquid-based units billed in Q4; full-year volumes were 49,180 tissue and 71,920 liquid units. Year-end cash was $29.0M. 2026 revenue guidance is $137–140M (+26–28% YoY). The company amended earnout terms with Exact Sciences: remaining payments of $15.0M (2026), $18.0M (2027), and $21.5M (2028) and issued warrants for 3.0M common shares at a $5.265 exercise price.
mdxhealth (NASDAQ: MDXH) announced initiation of Genomic Prostate Score (GPS) testing in the UK ProtecT randomized trial to validate GPS in an Active Surveillance cohort.
The ProtecT trial followed >1,500 men with localized prostate cancer for over two decades across Active Surveillance, Radical Prostatectomy, and Radiotherapy, providing long-term outcomes that the GPS-ProtecT study will leverage to test GPS's predictive power.
This follows a prior ProMPT validation and aims to generate randomized clinical-trial evidence supporting GPS's clinical utility and potential influence on guidelines, payer coverage, and provider adoption.
mdxhealth (NASDAQ: MDXH) reported Q3 2025 results with revenue $27.4M (+18% YoY), gross margin 65.2% (+4.0pp), and adjusted EBITDA $1.0M. The company reported a Q3 net loss of $8.0M (28% improvement YoY) and cash $32.0M at Sept 30, 2025. On Sept 15, 2025 mdxhealth closed the acquisition of Exosome Diagnostics from Bio-Techne, expanding the direct sales team to 60 reps and adding the ExoDx prostate test to its menu. Management suspended the planned germline product launch to prioritize ExoDx, Confirm mdx and GPS commercial integration.
MDxHealth (NASDAQ: MDXH) will release third quarter 2025 financial results for the period ended September 30, 2025 after market close on Wednesday, November 12, 2025.
The company will host a conference call and webcast with live Q&A on November 12, 2025 at 4:30 PM ET / 22:30 CET. Attendees are asked to access the webcast 15 minutes early. Dial-in numbers are provided for the United States, Belgium, the Netherlands, and the United Kingdom; the conference ID is 10203872. The live webcast URL is https://viavid.webcasts.com/starthere.jsp?ei=1738892&tp_key=76bbbf3f0a. A replay will be available on the company website following the call.
MDxHealth (NASDAQ: MDXH), a precision diagnostics company, has completed the acquisition of the ExoDx business from Bio-Techne Corporation. The acquisition includes the ExoDx Prostate (EPI) test, a CLIA-certified clinical laboratory, and related assets.
The total acquisition value is $15 million, structured as $5 million in stock paid at closing, with the remaining $10 million to be paid over 4 years in annual installments of $2.5 million (50% cash, 50% optional cash or stock). XMS Capital Partners served as financial advisor, while K&L Gates and Baker McKenzie provided legal counsel for the transaction.
MDxHealth (NASDAQ: MDXH) reported strong Q2 2025 results and announced a strategic acquisition. The company achieved $26.6 million in revenue, marking a 20% year-over-year increase and its 17th consecutive quarter of 20%+ growth. Notably, MDxHealth reached positive adjusted EBITDA of $1.4 million in Q2.
The company announced the acquisition of Bio-Techne's ExoDx business for $15 million, to be paid in cash and stock over 5 years. The deal includes the ExoDx Prostate test and CLIA-certified laboratory. The acquisition is expected to contribute over $20 million in revenue by 2026 and accelerate revenue growth to approximately 30%.
Q2 highlights include a 74% improvement in operating loss to $1.9 million, tissue-based test volume growth of 26%, and liquid-based test volume increase of 18%. The company reaffirmed its 2025 revenue guidance of $108-110 million.
MDxHealth (NASDAQ: MDXH), a precision diagnostics company, has announced key leadership changes. Michael Holder, an executive with over 30 years of experience, has been appointed to the Board of Directors as Audit Committee Chair, replacing Regine Slagmulder. Holder brings extensive expertise in corporate strategy, M&A, and governance, currently serving on boards including Cytek Biosciences.
Additionally, CFO Ron Kalfus has resigned effective July 30, 2025, after 6 years with the company. Scott McMahan, Vice President of Finance and Accounting, will assume CFO responsibilities on an interim basis.